Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01563978 · ClinicalTrials.gov registry record · Phase 2

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

A Phase 2 study of Rheumatoid Arthritis, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
266
Enrollment target
20
Study locations

NCT01563978 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by AstraZeneca. The registered enrollment target is 266 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01563978, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
266 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD). The study will last for 57 days.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG placebo
  • DRUG fostamatinib

Study Locations (20)

Florida

  • Research Site - Boca Raton
  • Research Site - Brandon
  • Research Site - Orlando
  • Research Site - Tampa
  • Research Site - Venice

Maryland

  • Research Site - Cumberland
  • Research Site - Frederick
  • Research Site - Hagerstown

California

  • Research Site - Huntington Beach
  • Research Site - Santa Maria

Missouri

  • Research Site - Florissant
  • Research Site - Richmond Heights

Alabama

  • Research Site - Huntsville

Connecticut

  • Research Site - Trumbull

Georgia

  • Research Site - Decatur

Indiana

  • Research Site - South Bend

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2012-04
Est. Completion 2013-01
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01563978

The ClinicalTrials.gov registry entry for NCT01563978 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01563978 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Maryland, California.

Frequently Asked Questions

What is clinical trial NCT01563978 about?

NCT01563978 is a clinical study titled "Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis". The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD). The study will last for 57 days.

What is the current status of trial NCT01563978?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2012-04. Estimated completion is 2013-01.

What conditions does trial NCT01563978 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01563978?

The interventions under investigation include: placebo (DRUG), fostamatinib (DRUG).

Who is sponsoring clinical trial NCT01563978?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01563978 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.